EA201992074A1 - Фармацевтическая композиция, содержащая селексипаг - Google Patents

Фармацевтическая композиция, содержащая селексипаг

Info

Publication number
EA201992074A1
EA201992074A1 EA201992074A EA201992074A EA201992074A1 EA 201992074 A1 EA201992074 A1 EA 201992074A1 EA 201992074 A EA201992074 A EA 201992074A EA 201992074 A EA201992074 A EA 201992074A EA 201992074 A1 EA201992074 A1 EA 201992074A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
aqueous
pharmaceutical composition
selexipag
composition containing
Prior art date
Application number
EA201992074A
Other languages
English (en)
Inventor
Клаус Хеллербранд
Александра Шликкер-Шпайн
Original Assignee
Актелион Фармасьютиклз Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201992074(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Актелион Фармасьютиклз Лтд filed Critical Актелион Фармасьютиклз Лтд
Publication of EA201992074A1 publication Critical patent/EA201992074A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к водным фармацевтическим композициям, содержащим соединение 2-{4-[N-(5,6-дифенилпиразин-2-ил)-N-изопропиламино]бутилокси}-N-(метилсульфонил)ацетамид; глицин; полисорбат 20; и водный фосфатный буфер, причем относительные количества соответствуют приведенному выше описанию, при этом значение рН указанной фармацевтической композиции составляет от около 7 до 8; к лиофилизированным фармацевтическим композициям, полученным из указанных водных композиций, и к их разведенным водным композициям, которые приемлемы для в/в введения. Изобретение дополнительно относится к способам получения указанных композиций и к их применению для лечения заболеваний и расстройств, относящихся к рецептору IP.
EA201992074A 2017-03-08 2018-03-07 Фармацевтическая композиция, содержащая селексипаг EA201992074A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017055406 2017-03-08
PCT/EP2018/055551 WO2018162527A1 (en) 2017-03-08 2018-03-07 Pharmaceutical composition comprising selexipag

Publications (1)

Publication Number Publication Date
EA201992074A1 true EA201992074A1 (ru) 2020-02-27

Family

ID=61655736

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992074A EA201992074A1 (ru) 2017-03-08 2018-03-07 Фармацевтическая композиция, содержащая селексипаг

Country Status (27)

Country Link
US (1) US20200129506A1 (ru)
EP (1) EP3592391B1 (ru)
JP (1) JP6964679B2 (ru)
KR (1) KR102593075B1 (ru)
CN (1) CN110430900B (ru)
AR (1) AR111570A1 (ru)
AU (1) AU2018229750B2 (ru)
BR (1) BR112019018420A2 (ru)
CA (1) CA3055010A1 (ru)
CL (1) CL2019002511A1 (ru)
CO (1) CO2019009221A2 (ru)
CR (1) CR20190455A (ru)
DO (1) DOP2019000250A (ru)
EA (1) EA201992074A1 (ru)
EC (1) ECSP19072294A (ru)
ES (1) ES2880009T3 (ru)
IL (1) IL269061A (ru)
JO (1) JOP20190204A1 (ru)
MA (1) MA47816A (ru)
MX (1) MX2019010598A (ru)
NI (1) NI201900090A (ru)
PE (1) PE20191492A1 (ru)
PH (1) PH12019502033A1 (ru)
PL (1) PL3592391T3 (ru)
SG (1) SG11201907804QA (ru)
TW (1) TWI764996B (ru)
WO (1) WO2018162527A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225297A1 (en) * 2019-05-06 2020-11-12 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
JP2022536623A (ja) * 2019-06-11 2022-08-18 アクテリオン ファーマシューティカルズ リミテッド 肺動脈性肺高血圧症の治療方法
JOP20220093A1 (ar) 2019-10-23 2023-01-30 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
JP2023512273A (ja) 2020-01-31 2023-03-24 アクテリオン ファーマシューティカルズ リミテッド 制御放出セレキシパグ組成物
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022215045A1 (en) * 2021-04-08 2022-10-13 Glenmark Pharmaceutical Limited Lyophilized composition comprising selexipag
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023209731A1 (en) * 2022-04-25 2023-11-02 Msn Laboratories Private Limited, R&D Center Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
TW202404594A (zh) * 2022-06-10 2024-02-01 日商日本新藥股份有限公司 醫藥組合物
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (ru) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
AR038535A1 (es) * 2002-02-22 2005-01-19 Schering Corp Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
SI2246336T1 (sl) 2008-02-28 2020-09-30 Nippon Shinyaku Co., Ltd. Inhibitor fibroze
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
EP2292231B1 (en) 2008-06-23 2015-10-21 Nippon Shinyaku Co., Ltd. Therapeutic agent for spinal canal stenosis
ES2611483T3 (es) 2008-06-23 2017-05-09 Nippon Shinyaku Co., Ltd. Agente terapéutico para enfermedad inflamatoria intestinal
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
PT3275871T (pt) 2009-06-26 2020-04-21 Nippon Shinyaku Co Ltd Cristais
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
JP2014514310A (ja) * 2011-04-19 2014-06-19 リグスホスピタル 毛細血管漏出の予防及び治療のために手術時に投与されるプロスタサイクリン及びその類似体
AU2012296953B2 (en) * 2011-08-12 2016-10-20 Ascendis Pharma A/S Sustained release composition of prostacyclin
EP2913047B1 (en) 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
EP4272763A3 (en) * 2013-09-11 2024-02-14 Eagle Biologics, Inc. Liquid protein formulations containing organophosphates
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017029594A1 (en) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
EP3192502A1 (en) * 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag

Also Published As

Publication number Publication date
PE20191492A1 (es) 2019-10-21
AU2018229750A1 (en) 2019-09-12
CO2019009221A2 (es) 2019-08-30
TWI764996B (zh) 2022-05-21
CA3055010A1 (en) 2018-09-13
PL3592391T3 (pl) 2021-11-02
MA47816A (fr) 2020-01-15
IL269061A (en) 2019-11-28
JP2020509070A (ja) 2020-03-26
EP3592391B1 (en) 2021-04-21
MX2019010598A (es) 2019-10-15
US20200129506A1 (en) 2020-04-30
BR112019018420A2 (pt) 2020-04-14
CN110430900B (zh) 2023-09-19
NI201900090A (es) 2020-03-11
KR102593075B1 (ko) 2023-10-23
WO2018162527A1 (en) 2018-09-13
JP6964679B2 (ja) 2021-11-10
DOP2019000250A (es) 2020-09-15
TW201842910A (zh) 2018-12-16
EP3592391A1 (en) 2020-01-15
ECSP19072294A (es) 2019-11-30
AU2018229750B2 (en) 2023-11-23
SG11201907804QA (en) 2019-09-27
PH12019502033A1 (en) 2020-06-15
CN110430900A (zh) 2019-11-08
ES2880009T3 (es) 2021-11-23
JOP20190204A1 (ar) 2019-09-05
CL2019002511A1 (es) 2020-01-17
CR20190455A (es) 2019-11-12
AR111570A1 (es) 2019-07-31
KR20190122803A (ko) 2019-10-30

Similar Documents

Publication Publication Date Title
EA201992074A1 (ru) Фармацевтическая композиция, содержащая селексипаг
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
EA202092003A1 (ru) Соединения для лечения болезни гентингтона
EA202090573A1 (ru) Составы нирапариба
SA519401647B1 (ar) y مركبات ببتيد تيروسين-تيروسين الحلقية المقترنة بجسم مضاد كمعدلات لمستقبلات الببتيد العصبي
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA202090500A1 (ru) Кристаллические формы иммуномодуляторов
EA202090536A1 (ru) Кристаллические формы 3-замещенного 1,2,4-оксадиазола
BR112018009534A2 (pt) composição farmacêutica contendo 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi }-n-(metilsulfonil)acetamida
EA201791829A1 (ru) Амидные соединения в качестве агонистов рецептора 5-ht
EA202192845A1 (ru) Новые композиции, содержащие мелфлуфен
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA202092955A1 (ru) Алкоксизамещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза
EA202191477A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202091293A1 (ru) Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
EA201792170A1 (ru) Производные индола
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
EA201992829A1 (ru) Карбоксильные производные в качестве ингибиторов протеинкиназ
EA202090982A1 (ru) Производные бензимидазола и варианты их применения